|
|
|
| Effect of Cytochrome CYP4502C19(CYP2C19) Gene Polymorphism on Antiplatelet Effect of Clopidogrel in Patients with Acute Coronary Syndrome |
| ZHUANG De-rong, HE Sheng-hu, CAI Ding-hua, et al |
| Cardiovascular Medicine Department, Jiangdu People's Hospital of Yangzhou, Yangzhou, Jiangdu, 225200 |
|
|
|
|
Abstract 【Objective】To investigate the effect of cytochrome P450CYP2C19 gene polymorphism on antiplatelet effect of clopidogrel in patients with acute coronary syndrome (ACS).【Methods】From January 2015 to June 2017, 100 patients with ACS were selected. According to clopidogrel resistance, the patients were divided into two groups: resistance group (n=50) and non-resistance group (n=50). The platelet aggregation function and genotypes of the two groups were measured. The allele frequency, genotype frequency and distribution of two single nucleotide polymorphisms (SNPs) were analyzed.【Results】 The distribution rate of CYP2C19*2 (rs4244285) GG in resistant group was significantly lower than that in the non resistant group, and the distribution of GA+AA type was significantly higher than that in the non resistant group (P<0.05). The platelet aggregation test induced by adenosine diphosphate showed that the platelet aggregation rate of CYP2C19*2, CYP2C19*3 gene variant was significantly higher than that of the wild type (P<0.05).【Conclusion】Clopidogrel resistance is closely associated with CYP2C19*2 (rs4244285) GA+AA genotype in patients with ACS. The detection of clopidogrel genotype may provide a reference for clinical application of clopidogrel.
|
|
Received: 27 February 2018
|
|
|
|
|
|
[1] Bentley LR, Aguilar D, Riddle MC,et al. Rationale, design, and baseline characteristics in evaluation of lixisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo[J].Am Heart J,2015, 169(5):631-638.
[2] 崔波, 郭莹, 张翼. 急性冠脉综合症介入治疗前早期应用替罗非班的临床研究[J].湖南师范大学学报(医学版), 2009, 6(4):33-36.
[3] Lee S, Hizoh I, Kovacs A, et al. Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome[J].Platelets,2015, 27(2):159-167.
[4] 宋彦增, 刘振坤. 替格瑞洛治疗不稳定型心绞痛的临床疗效研究[J].湖南师范大学学报(医学版), 2016, 13(4):49-51.
[5] Almendro DM, Gonzalez TL, Garcia AA, et al. Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively[J].Am J Cardiol,2015, 115(8):1019-1026.
[6] Qaderdan K, Ishak M, Heestermans AA, et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older-rationale and design of the popular AGE study[J].Am Heart J,2015, 170(5):981-985.
[7] Wei YQ, Wang DG, Yang H, et al. Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome[J].PLoS One,2015, 10(7):e0132561.
[8] Wang XQ, Shen CL, Wang BN, et al. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome[J].Gene,2015, 558(2):200-207.
[9] Motoyama S, Ito H, Sarai M, et al. Reply: plaque characterization by coronary computed tomography angiography and association with acute coronary syndrome[J].J Am Coll Cardiol,2016, 67(4):458-459.
[10] 商永华, 蒋小玲. 缺血性脑卒中患者CYP2C19基因代谢型、联用药物与氯吡格雷抵抗关系的研究[J].福建医药杂志, 2016, 38(4):65-68.
[11] 阴淑莹, 王翠艳, 魏芳晶. 急性冠脉综合征CYP2C19基因多态性与氯吡格雷抵抗的相关性研究[J].陕西医学杂志, 2016, 45(5):525-526.
[12] 夏金喜, 肖建民, 万德立, 等. 急性冠脉综合征PCI术后患者CYP2C19*2、CYP2C19*3基因多态性与氯吡格雷抵抗及临床预后的关系[J].中国心血管病研究, 2015, 13(8):731-734.
[13] Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015, 65(6):494-500.
[14] 谭洁, 刘彦, 林琳. 经皮冠状动脉介入术后病人CYP2C19基因多态性与氯 吡格雷抵抗的相关性研究[J].临床心血管病杂志, 2013, 29(2):209-211.
[15] 董瑨堃, 孟舒, 陈俊文, 等. 血栓弹力图预测CYP2C19基因型对指导经皮冠状动脉介入术后氯吡格雷治疗的价值[J].第二军医大学学报, 2013, 4(7):732-737. |
|
|
|
2018, Vol. 35 
